Lataa...
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel
At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma (pdac) is the lowest of any cancer. The currently approved treatment options for metastatic pdac in the United States are folfirinox [irinotecan–fluorouracil (5fu)–leucovorin (lv)–o...
Tallennettuna:
| Julkaisussa: | Curr Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Multimed Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7253755/ https://ncbi.nlm.nih.gov/pubmed/32489272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5893 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|